"Since 2003, AACE and the ADA have worked together to provide recommendations for treatment of inpatient hyperglycemia, and these efforts have contributed to a growing national movement viewing the management of hyperglycemia in hospitals as a quality care measure," Dr. Etie S. Moghissi, AACE Chair of Inpatient Glycemic Control Task Force said.
Recognizing the critical importance of controlling hyperglycemic states in conjunction with the results of recent randomized trials such as NICE-SUGAR, the two organizations recently convened a Consensus Panel to extensively review the most current literature and up-to-date recommendations for treatment of hyperglycemia in the hospital.
"The central goal of the ADA/AACE inpatient task force is to identify reasonable, achievable, and safe glucose targets, and to describe the protocols, procedures, and system improvements needed to achieve inpatient optimal glucose control efficiently and safely," Dr. Mary Korytkowski, ADA Chair of Inpatient Glycemic Control Task Force said.
Complete recommendations from the panel will be published in Endocrine Practice and Diabetes Care later in the spring. Until more information is available, it seems reasonable for clinicians to treat critical care patients with the less intensive - yet good - glucose control strategies used in the conventional arm of the NICE-SUGAR trial.
About The NICE-SUGAR Study
Hyperglycemia in the hospital, whether it occurs in patients with known diabetes or is temporarily stress-induced, has long been known to be associated with poor outcomes such as longer length of stay, increased rates of infection, and in-hospital death. Observational studies and early randomized trials have suggested that lowering glucose levels can improve outcomes, especially in critical care patients treated with
|SOURCE American Association of Clinical Endocrinologists; American Diabetes Association|
Copyright©2009 PR Newswire.
All rights reserved